Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with HIPEC for advanced peritoneal implantation tumors
ChiCTR-OPC-17013522Phase 4Suspended
- Sponsor
- Hangzhou Cancer Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in peritoneal carcinomatosis (PC), sponsored by Hangzhou Cancer Hospital. Primary endpoint: Progression-free survival. Started Nov 2017; status: suspended.
02
Drugs
Rivoceranib
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR-OPC-17013522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013522.